Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Advances in treating CMV

    Project Inform Perspective
    |August 13, 2002
    PubMed
    Summary
    This summary is machine-generated.

    New research indicates valganciclovir, an oral medication, is as effective as intravenous ganciclovir for treating cytomegalovirus (CMV) retinitis. This marks a significant advancement in oral antiviral therapy for CMV infections.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same journal

    Everything antiretroviral: 5th IAS conference, Cape Town, South Africa.

    Project Inform perspective·2012
    Same journal

    Well implemented, President Obama's national HIV/AIDS strategy is precisely what is needed to further control HIV/AIDS.

    Project Inform perspective·2011
    Same journal

    Finding health care; preparing for the future.

    Project Inform perspective·2011
    Same journal

    Protecting people with HIV in the California budget.

    Project Inform perspective·2010
    Same journal

    Current drugs in clinical study.

    Project Inform perspective·2010
    Same journal

    HIV treatment information.

    Project Inform perspective·2010
    See all related articles

    Area of Science:

    • Ophthalmology
    • Infectious Diseases
    • Pharmacology

    Background:

    • Cytomegalovirus (CMV) retinitis remains a significant cause of vision loss, particularly in immunocompromised individuals.
    • Intravenous (IV) ganciclovir has been the standard treatment, requiring administration in clinical settings.
    • The development of effective oral antiviral agents is crucial for improving patient compliance and accessibility.

    Discussion:

    • This study presents findings on a novel oral formulation of ganciclovir, valganciclovir, for CMV retinitis treatment.
    • Comparative analysis demonstrates equivalent efficacy between oral valganciclovir and IV ganciclovir.
    • The results challenge the necessity of IV administration for effective CMV retinitis management.

    Key Insights:

    • Oral valganciclovir offers a viable and effective alternative to IV ganciclovir for CMV retinitis.

    Related Experiment Videos

  • This represents a breakthrough in oral antiviral therapy, potentially improving patient outcomes and reducing healthcare burdens.
  • The study establishes a new standard of care, prioritizing patient convenience without compromising therapeutic effectiveness.

    • Outlook:

    • Further research may explore long-term outcomes and cost-effectiveness of oral valganciclovir.
    • Wider adoption of oral valganciclovir is anticipated, transforming CMV retinitis treatment paradigms.
    • This advancement could pave the way for similar oral formulations of antiviral drugs for other opportunistic infections.